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What interventions 
can help patients stop
using chewing tobacco?
■ Evidence-Based Answer 
Nicotine replacement therapy (NRT), including
gum and patches, decreases cravings and short-
term abstinence rates, but does not improve 
long-term abstinence (strength of recommendation
[SOR]: B, meta-analysis of small randomized 
controlled studies [RCT]). 
It is unclear if bupropion has an effect on 
cessation rates (SOR: B, small RCTs with conflict-
ing results). Behavioral interventions increase
abstinence rates for smokeless tobacco users (SOR:
B, meta-analysis of small RCTs).
■ Evidence Summary
Use of smokeless tobacco can lead to nicotine
dependence and cause periodontal disease, leuko-
plakia, cancer, and possibly cardiovascular dis-
ease.1–3 Patients who abruptly stop using smokeless
tobacco may experience withdrawal symptoms
similar to that observed in smokers.3
Nicotine gum
A small double-blind study randomized 79 male
smokeless tobacco users to chew nicotine gum 
(0 mg, 2 mg, or 4 mg) for 5 days.4 Sixty patients
completed the study. No significant differences in
withdrawal symptoms, including cravings, concen-
tration, or restlessness, were noted among the 
3 groups (P>.05). However, further analysis
demonstrated that patients with high blood levels
of cotinine who received nicotine gum 2 mg expe-
rienced decreased cravings compared with placebo
(P<.001), and a trend towards decreased cravings
with 4 mg gum was noted (P<.06). Limitations of
this study: quit rates were not reported, partici-
pants did not have to be motivated to quit smoke-
less tobacco in order to enroll, and it is not known
if patients were counseled about the appropriate
“chew and park” technique for nicotine gum.
Another study randomized 234 male smoke-
less tobacco users to receive group behavioral
treatment plus nicotine gum 2 mg (B/NRT); group
behavioral treatment plus placebo (B/Pl); minimal
contact plus nicotine gum 2 mg (MC/NRT); or
minimal contact plus placebo (MC/Pl).5
Group behavioral treatment consisted of 8
group counseling sessions 45 to 60 minutes in
length; minimal contact involved 4 brief one-on-one
sessions with a nurse. Patients chewed a minimum
of 6 pieces of nicotine or placebo gum per day.
At 4 weeks, point prevalence abstinence rates
were as follows: B/NRT, 63.6%; B/Pl, 66%;
MC/NRT, 35.3%; and MC/Pl, 48.1% (P<.01).
Abstinence rates remained significantly different at
1 and 6 month follow-ups, but not at 12 months.
Post-hoc logistic regression favored group behav-
ioral therapy plus NRT at 6 months. Moreover,
survival analysis of continuous prevalence rates
demonstrated that the least effective treatment was
minimal contact plus NRT.
The authors theorized that nicotine gum may
actually worsen risk of relapse in smokeless tobac-
co users due to behavioral similarities associated
with use, but that behavioral treatment may help
regain abstinence after a lapse. Gum users experi-
enced lessened withdrawal symptoms including
cravings, irritability, anxiety, and difficulty concen-
trating (P<.01). Results indicate that behavioral
interventions may be more effective than NRT;
however, low doses of nicotine gum were used.
Nicotine transdermal patches
A randomized double-blind study examined nico-
tine transdermal patches in smokeless tobacco
users.6 Researchers recruited 422 participants from
a Minnesota college campus and surrounding met-
ropolitan area through advertisements; they were
randomly assigned to nicotine patch plus mint
snuff (a nicotine-free product), nicotine patch and
no mint snuff, placebo patch plus mint snuff, or
placebo patch and no mint snuff. The patch was
dosed as 21-mg patch for 6 weeks, 14-mg patch
for 2 weeks, and 7-mg patch for 2 weeks. All
patients participated in 8 weekly individual 10-
minute sessions with a therapist.
Continuous 10-week abstinence rates were
69% for nicotine patch and mint snuff, 58% for
nicotine patch and no mint snuff, 46% for place-
bo patch and mint snuff, and 51% for placebo
patch and no mint snuff (P=.002). After 15 weeks
the abstinence rates were no longer different
between the treatment groups. Patch users experi-
enced lower total withdrawal scores (P=.002) as
well as decreased craving (P<.001), irritability
(P<.001), and restlessness (P=.019). Total with-
drawal scores were not improved for mint snuff
users; however, subsets of total withdrawal scores
were lower for cravings (P=.005), irritability
(P=.046), and anxiety (P=.012).
Meta-analysis
The Cochrane Database of Systematic Reviews
published a meta-analysis of 6 studies that exam-
ined NRT or bupropion in smokeless tobacco
users.3 The primary outcome for the meta-analysis
was tobacco abstinence 6 months or more after
the intervention. Neither nicotine patches (odds
ratio [OR]=1.16; 95% confidence interval [CI],
0.88–1.54) nor nicotine gum (OR=0.98; 95% CI,
0.59–1.63) were shown to improve abstinence
over placebo at 6 months. The authors highlight
the need for larger studies that compare different
NRT products, doses, and duration.
One small randomized trial of bupropion was
included, but it found no effect on tobacco absten-
tion (OR=1.00; 95% CI, 0.23–4.37). Another
small RCT found an effect; however, it was
excluded from the meta-analysis because subjects
were followed for only 3 months. The meta-analy-
sis also concluded that behavioral interventions
appear to be effective for increasing tobacco absti-
nence rates. Results were heterogeneous, and
study quality was mixed. One post-hoc finding
appeared to show that most effective behavioral
interventions were coupled with an oral exam
with direct feedback. 
■ Recommendations from Others
The United States Department of Health and
Human Services recommends that smokeless tobac-
co users should be treated with the same counseling
and interventions utilized for smokers, but com-
mented that evidence is currently insufficient to sug-
gest that NRT increases long-term abstinence.7
British guidelines concluded that no evidence clear-
ly shows that nicotine gum or patches are effective
cessation aids for smokeless tobacco users.2
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■ Clinical Commentary
NRT not recommended for smokeless
users; try bupropion, behavioral therapy
Smokeless tobacco users are a special tobacco
user population with a limited research base.
Although it seems counterintuitive, nicotine
replacement therapy (nicotine gum and the
nicotine patch) is not recommended for this
population. Using the tobacco use and quit 
history, treatment may include bupropion while
employing standard behavioral therapies: intra-
treatment social support, extra-treatment social
support, and problem solving skills training.
After setting a quit date, prepare the patient for
the quit, and following the quit attempt focus on
relapse prevention. Frequent follow-up visits
provide intra-treatment social support and 
promotes development of extra-treatment (eg,
telephone or computer based quit lines or 
individuals) social support while providing 
practical problem solving. 
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